Screener
Theravance Biopharma TBPH Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Facilities and other allocated expenses (Research and development) | 562 | 778 | 1,365 | 1,664 |
| Supporting general and administration functions 1 | 5,619 | 8,221 | 13,579 | 15,479 |
| Sales and marketing, and medical affairs 1 | 4,985 | 6,653 | 11,896 | 13,958 |
| Share-based compensation | 4,138 | 4,543 | 7,614 | 9,420 |
| Total recurring operating expenses | 18,888 | 28,920 | 42,437 | 58,742 |
| Restructuring expenses (including share-based compensation) | 4,031 | — | 7,664 | — |
| Transaction-related expenses | 6,089 | — | 6,089 | — |
| Total operating expenses | 29,008 | 28,920 | 56,190 | 58,742 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's business segments — stock-based comp?
- Theravance Biopharma (TBPH) reported business segments — stock-based comp of $4.14M in Q2 2026.
- How has Theravance Biopharma's business segments — stock-based comp changed year-over-year?
- Theravance Biopharma's business segments — stock-based comp decreased by 8.9% year-over-year, from $4.54M to $4.14M.
- What is the long-term trend for Theravance Biopharma's business segments — stock-based comp?
- Over 2 years (2023 to 2025), Theravance Biopharma's business segments — stock-based comp has grown at a -14.1% compound annual growth rate (CAGR), from $25.01M to $18.48M.
- What does business segments — stock-based comp mean?
- This represents the non-cash expense related to equity-based awards granted to employees and executives as part of their total compensation package. It is a critical metric for understanding the dilution impact and the alignment of management incentives with shareholder interests.
Ask your AI about Theravance Biopharma's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude